Research page

2TZ

Tirzepatide

2TZ 20 mg. For research use only2TZ 30 mg. For research use only
Calculate dose

Specification

Name2TZ · Tirzepatide
Catalog sizes20 mg, 30 mg
Adopted bacteriostatic water10 mg + 1.0 mL = 10 mg/mL · 15 mg + 1.5 mL = 10 mg/mL · 20 mg + 2.0 mL = 10 mg/mL · 25 mg + 2.5 mL = 10 mg/mL · 30 mg + 3.0 mL = 10 mg/mL

Overview

2TZ is the TRACE catalog name for tirzepatide, a peptide that binds the GIP and GLP-1 receptors. Tirzepatide is FDA-approved only as specific branded medicines. This research vial is not that product.

Mechanism under study

The literature describes it as a dual agonist. The GLP-1 part has been studied in relation to satiety, gastric emptying, and glucose-dependent insulin. The GIP part has been studied as a second incretin signal. TRACE does not translate that into a schedule.

What published research has reported

A phase 3 trial published in The New England Journal of Medicine in 2022 studied once-weekly tirzepatide in adults with obesity or overweight, inside the program for that branded medicine. The results belong to that product and that protocol, not to this vial.

Composition and mass

The catalog offers 20 mg and 30 mg. The same rule as RTA: always 10 mg/mL, so 20 mg takes 2.0 mL and 30 mg takes 3.0 mL. The rule also covers 10, 15, and 25 mg, which are not in the 2TZ catalog.

Reconstitution

mgmLmg/mL
101.010On the rule, not in the catalog
151.510On the rule, not in the catalog
202.010In the catalog
252.510On the rule, not in the catalog
303.010In the catalog

Calculate dose

Storage and handling

Lyophilized material cool, dry, and protected from light. Dissolved: 2–8 °C, not frozen, 28-day horizon.

Regulatory status

Tirzepatide is FDA-approved only as branded medicines. 2TZ is not that medicine. It is not a supplement or a food. It is not intended to diagnose, treat, cure, or prevent any disease.

References